NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 900K 1.8M 2.7M FY10: 10K FY11: 10K FY12: 772K FY13: 809K FY14: 1.5M FY15: 1.7M FY16: 623K FY17: 336K FY18: 412K FY19: 2.4M FY20: 1.3M FY21: 1M FY22: 1.7M FY23: 1.9M FY24: 1.4M FY25: 1.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY10: -15.4M FY11: -26.8M FY12: -43.8M FY13: -55.5M FY14: -101.1M FY15: -126.3M FY16: -79.3M FY17: -54.7M FY18: -41.5M FY19: -28M FY20: -86.6M FY21: -52.7M FY22: -67.2M FY23: -55.5M FY24: -66.5M FY25: -59.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-600M -400M -200M 0 200M 400M 600M FY97: -2.6M FY98: -4.7M FY99: -5.6M FY00: -12.8M FY01: -10.9M FY02: -12.8M FY03: -5.8M FY04: -8.5M FY05: -9.9M FY06: -1.4M FY07: -21.2M FY08: -22.3M FY09: -27M FY10: -27.4M FY11: -32.8M FY12: -67.3M FY13: -65.8M FY14: -135.6M FY15: -114.7M FY16: -80.2M FY17: -73.1M FY18: -35.8M FY19: -20.8M FY20: -529.8M FY21: 179.1M FY22: -105M FY23: -62.6M FY24: -83.8M FY25: -60.2M FY98 FY01 FY04 FY07 FY10 FY13 FY16 FY19 FY22 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M FY10: -6.4M FY11: -14.7M FY12: -22.8M FY13: -37.8M FY14: -54.6M FY15: -78.6M FY16: -55.7M FY17: -36.5M FY18: -34.6M FY19: -31.9M FY20: -32.1M FY21: -38.3M FY22: -52.8M FY23: -53.6M FY24: -57M FY25: -44.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY10: -6.4M FY11: -14.8M FY12: -22.8M FY13: -37.8M FY18: -34.6M FY19: -32M FY20: -38.7M FY21: -44.3M FY22: -55.7M FY23: -57.1M FY24: -58M FY25: -46.3M FY11 FY13 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 500M 1B 1.5B FY10: 67.1M FY11: 94.2M FY19: 564.2K FY20: 725.1K FY21: 1M FY22: 1M FY23: 1.1M FY24: 1.2B FY25: 1.5B FY10 FY11 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '10: -0.41 Q1 '11: -0.43 Q2 '11: -0.44 Q3 '13: -3.72 Q4 '13: -1.99 Q1 '14: -2.33 Q2 '14: -2.38 Q3 '14: -2.08 Q4 '14: -2.32 Q1 '15: -2.11 Q2 '15: -2.54 Q3 '15: -1.94 Q4 '15: -1.57 Q1 '16: -0.96 Q2 '16: -0.24 Q3 '16: -0.77 Q4 '16: -0.75 Q1 '17: -0.77 Q2 '17: -0.66 Q3 '17: -0.46 Q4 '17: -0.31 Q1 '18: -0.32 Q4 '10 Q3 '13 Q2 '14 Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.